Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

20.09.2017: Press release: WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit. WILEX AG today announced that its subsidiary, Heidelberg Pharma Research GmbH, Ladenburg, Germany, will present at the 8th Annual World ADC Summit taking place on 20-22 September in San Diego, CA, USA.. ...More





Seite gelesen: 122607 | Heute: 276